Literature DB >> 24900796

Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors.

Xiaojun Zhang1, Wen Jiang1, Swanee Jacutin-Porte1, Peter W Glunz1, Yan Zou1, Xuhong Cheng1, Alexandra H Nirschl1, Nicholas R Wurtz1, Joseph M Luettgen1, Alan R Rendina1, Gang Luo1, Timothy M Harper1, Anzhi Wei2, Rushith Anumula3, Daniel L Cheney1, Robert M Knabb2, Pancras C Wong1, Ruth R Wexler1, E Scott Priestley1.   

Abstract

Inhibitors of the Tissue Factor/Factor VIIa (TF-FVIIa) complex are promising novel anticoagulants that show excellent efficacy and minimal bleeding in preclinical models. On the basis of a zwitterionic phenylglycine acylsulfonamide 1, a phenylglycine benzylamide 2 was shown to possess improved permeability and oral bioavailability. Optimization of the benzylamide, guided by X-ray crystallography, led to a potent TF-FVIIa inhibitor 18i with promising oral bioavailability, but promiscuous activity in an in vitro safety panel of receptors and enzymes. Introducing an acid on the pyrrolidine ring, guided by molecular modeling, resulted in highly potent, selective, and efficacious TF-FVIIa inhibitors with clean in vitro safety profile. The pyrrolidine acid 20 showed a moderate clearance, low volume of distribution, and a short t 1/2 in dog PK studies.

Entities:  

Keywords:  TF-FVIIa inhibitor; aminoisoquinoline; anticoagulant; phenylglycinamide; phenylpyrrolidine; structure-based drug design

Year:  2013        PMID: 24900796      PMCID: PMC4027585          DOI: 10.1021/ml400453z

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  16 in total

1.  Factor VIIa modified in the 170 loop shows enhanced catalytic activity but does not change the zymogen-like property.

Authors:  K Soejima; J Mizuguchi; M Yuguchi; T Nakagaki; S Higashi; S Iwanaga
Journal:  J Biol Chem       Date:  2001-02-02       Impact factor: 5.157

2.  The antithrombotic and anti-inflammatory effects of BCX-3607, a small molecule tissue factor/factor VIIa inhibitor.

Authors:  C Shane Arnold; Cynthia Parker; Ramanda Upshaw; Hans Prydz; Pooran Chand; Pravin Kotian; Shanta Bantia; Y Sudhakar Babu
Journal:  Thromb Res       Date:  2006       Impact factor: 3.944

3.  Potent 4-amino-5-azaindole factor VIIa inhibitors.

Authors:  Huiyong Hu; Aleksandr Kolesnikov; Jennifer R Riggs; Kieron E Wesson; Robin Stephens; Ellen M Leahy; William D Shrader; Paul A Sprengeler; Michael J Green; Ellen Sanford; Margaret Nguyen; Erik Gjerstad; Ronnel Cabuslay; Wendy B Young
Journal:  Bioorg Med Chem Lett       Date:  2006-06-21       Impact factor: 2.823

4.  Design, synthesis and biological activity of selective and orally available TF/FVIIa complex inhibitors containing non-amidine P1 ligands.

Authors:  Masanori Miura; Norio Seki; Takanori Koike; Tsukasa Ishihara; Tatsuya Niimi; Fukushi Hirayama; Takeshi Shigenaga; Yumiko Sakai-Moritani; Ayako Tagawa; Tomihisa Kawasaki; Shuichi Sakamoto; Minoru Okada; Mitsuaki Ohta; Shin-Ichi Tsukamoto
Journal:  Bioorg Med Chem       Date:  2006-10-04       Impact factor: 3.641

5.  BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies.

Authors:  Pancras C Wong; Joseph M Luettgen; Alan R Rendina; Charles A Kettner; Baomin Xin; Robert M Knabb; Ruth Wexler; E Scott Priestley
Journal:  Thromb Haemost       Date:  2010-06-29       Impact factor: 5.249

6.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

Review 7.  Tissue factor - a therapeutic target for thrombotic disorders.

Authors:  Donald S Houston
Journal:  Expert Opin Ther Targets       Date:  2002-04       Impact factor: 6.902

Review 8.  The inhibitors of the tissue factor:factor VII pathway.

Authors:  Paolo Golino
Journal:  Thromb Res       Date:  2002-05-01       Impact factor: 3.944

9.  Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time.

Authors:  James A Szalony; Osman D Suleymanov; Anita K Salyers; Susan G Panzer-Knodle; Jason D Blom; Rhonda M LaChance; Brenda L Case; John J Parlow; Michael S South; Rhonda S Wood; Nancy S Nicholson
Journal:  Thromb Res       Date:  2003       Impact factor: 3.944

10.  Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.

Authors:  Michael S South; Brenda L Case; Rhonda S Wood; Darin E Jones; Michael J Hayes; Thomas J Girard; Rhonda M Lachance; Nancy S Nicholson; Michael Clare; Anna M Stevens; Roderick A Stegeman; William C Stallings; Ravi G Kurumbail; John J Parlow
Journal:  Bioorg Med Chem Lett       Date:  2003-07-21       Impact factor: 2.823

View more
  3 in total

1.  Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.

Authors:  Nicholas R Wurtz; Brandon L Parkhurst; Wen Jiang; Indawati DeLucca; Xiaojun Zhang; Vladimir Ladziata; Daniel L Cheney; Jeffrey R Bozarth; Alan R Rendina; Anzhi Wei; Joseph M Luettgen; Yiming Wu; Pancras C Wong; Dietmar A Seiffert; Ruth R Wexler; E Scott Priestley
Journal:  ACS Med Chem Lett       Date:  2016-09-17       Impact factor: 4.345

2.  Diastereo- and regioselective petasis aryl and allyl boration of ninhydrins towards synthesis of functionalized indene-diones and dihydrobenzoindeno-oxazin-ones.

Authors:  Ayon Sengupta; Suvendu Maity; Pinaki Saha; Prasanta Ghosh; Sonali Rudra; Chhanda Mukhopadhyay
Journal:  Mol Divers       Date:  2022-08-01       Impact factor: 3.364

3.  Reactivity and Synthetic Applications of Multicomponent Petasis Reactions.

Authors:  Peng Wu; Michael Givskov; Thomas E Nielsen
Journal:  Chem Rev       Date:  2019-08-27       Impact factor: 60.622

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.